Overexpressing RUNX2 in implanted prostate cancer cells [5] activated genes required for osteolytic illness, such as PTH-related protein (PTHrP) [87] and interleukin 8 (IL8) [88]. This evidence concerns the gene PTHLH and prostate carcinoma.